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http://dx.doi.org/10.1016/j.ccr.2014.06.014SUMMARYTheMYC oncogene regulates gene expression through multiple mechanisms, and its overexpression culmi-
nates in tumorigenesis. MYC inactivation reverses turmorigenesis through the loss of distinguishing features
of cancer, including autonomous proliferation and survival. Here we report that MYC viamiR-17-92maintains
a neoplastic state through the suppression of chromatin regulatory genes Sin3b, Hbp1, Suv420h1, and Btg1,
as well as the apoptosis regulator Bim. The enforced expression of miR-17-92 prevents MYC suppression
from inducing proliferative arrest, senescence, and apoptosis and abrogates sustained tumor regression.
Knockdown of the five miR-17-92 target genes blocks senescence and apoptosis while it modestly delays
proliferative arrest, thus partially recapitulating miR-17-92 function. We conclude that MYC, via miR-17-92,
maintains a neoplastic state by suppressing specific target genes.INTRODUCTION
Cancers are often dependent on or addicted to the initiating on-
cogenes for the maintenance of the malignant phenotype (Chin
et al., 1999; Felsher and Bishop, 1999; Huettner et al., 2000;
Weinstein, 2002). The inactivation of a single driver oncogene
can result in rapid and sustained tumor regression. Oncogene
addiction has been exploited clinically in targeted therapies,
such as imatinib for BCR-ABL-driven chronic myelogenous
leukemia, gefitinib for lung adenocarcinoma with EGFR muta-
tions, and vemurafenib for melanomas with B-RAF mutations
(Chapman et al., 2011; Druker et al., 1996; Ladanyi and Pao,
2008). Hence, the targeted inactivation of oncogenes appears
to be a generalizable approach for the treatment of many
cancers.
The MYC oncogene is overexpressed in over half of human
cancers (Dang, 2012). To study the role of MYC in the initiation
and maintenance of tumorigenesis, some investigators haveSignificance
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reversible models of cancer (Gossen and Bujard, 1992). In these
mouse models, the overexpression of a conditional MYC trans-
gene initiates tumorigenesis, and its inactivation results in rapid,
complete, and sustained tumor regression. MYC inactivation is
associated with the loss of many of the distinguishing features
of tumorigenesis and results in proliferative arrest, apoptosis,
differentiation, and senescence, as well as the shutdown of
angiogenesis (D’Cruz et al., 2001; Felsher and Bishop, 1999; Ha-
nahan andWeinberg, 2011; Shachaf et al., 2004;Wu et al., 2007).
MYC is a transcriptional regulator of amultitude of genes, but it
is unclear if any of these genes are responsible for MYC main-
taining a neoplastic state (Dang, 2012). Recently, it has been
shown that MYC may regulate gene expression as a general
transcriptional amplifier (Lin et al., 2012; Nie et al., 2012). How-
ever, it has been pointed out that this would not explain how
MYC can suppress gene expression or regulate gene expression
in a specific manner (Walz et al., 2013). MYC has also beenncers. MYC overexpression coordinates the expression of
oplastic properties. However, it was unclear which specific
ere we show that MYCmaintains a neoplastic state through
ls specific chromatin regulatory and survival programs.MYC
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MYC through miR-17-92 Maintains a Neoplastic Stateshown to regulate the expression of several microRNAs,
including the polycistronic miR-17-92 cluster (Bui and Mendell,
2010; O’Donnell et al., 2005; Sander et al., 2008). The miR-17-
92 cluster is overexpressed in human lymphomas (He et al.,
2005). Notably, overexpression of miR-17-92 cooperates with
MYC to induce lymphomagenesis, while deletion of miR-17-92
induces the death of lymphoma cells (He et al., 2005; Mu et al.,
2009).
We hypothesized thatmiR-17-92 is causally responsible for at
least part of the mechanism by which MYC maintains a
neoplastic state (Figure 1A). Here we found that MYC, through
miR-17-92, regulates the expression of specific chromatin regu-
latory genes, such as Sin3b, Hbp1, Suv420h1, and Btg1, as well
as the apoptosis regulator Bim. Upon MYC inactivation, the
downregulation of miR-17-92 and the corresponding induction
of these target genes are causally required for the activation of
the apoptosis and senescence programs and sustained tumor
regression. Hence, MYC suppression of these genes is one of
the required mechanisms for maintaining a neoplastic state.
RESULTS
SustainedmiR-17-92 Expression Rescues MYC
Addiction In Vitro and In Vivo
We examined the level of several microRNAs known to be regu-
lated by MYC by using real-time quantitative PCR in three lym-
phoma cell lines from Em-tTA/tet-O-MYC mice (O’Donnell et al.,
2005; Sander et al., 2008). Upon MYC inactivation with doxycy-
cline treatment, allmembersof themiR-17-92clusterweredown-
regulated, while miR-15/16 and miR-26 were upregulated in a
time-dependent manner (Figure S1A available online). Similarly,
in MYC-driven hepatocellular carcinoma derived from LAP-tTA/
tet-O-MYC transgenic mice, miR-17-92, but not miR-15/16 and
miR-26, was downregulated upon MYC inactivation (Kota et al.,
2009; Shachaf et al., 2004) (Figure S1B). Thus, MYC generally
regulates the expression ofmiR-17-92 in tumor cells.
We speculated that miR-17-92 was responsible for maintain-
ing at least some of the distinguishing features of cancer in
MYC-induced tumors (Figure 1A). To determine whether consti-
tutive expression ofmiR-17-92 could rescue any of the effects of
MYC inactivation, we retrovirally infected MYC-induced lym-
phomas with the murine stem cell virus containing miR-17-92
(MSCV-miR-17-92) and then confirmed that expression of miR-
17-92 was maintained even after MYC inactivation (Figures 1B
and S1C). RetroviralmiR-17-92 expression abrogated the induc-
tion of proliferative arrest, apoptosis, and senescence, which we
previously described as consequences of MYC suppression
(Felsher and Bishop, 1999; Wu et al., 2007). The proliferation
was sustained over a 5-day time course in miR-17-92-express-
ing cells after MYC inactivation, as shown by the S/G2/M
population in the flow cytometric analysis of cell cycle distribu-
tions (Figures 1C and S1D). The induction of apoptosis by
MYC inactivation was blocked by miR-17-92 as shown by the
subG1 population and the 7-AAD/Annexin V double positive
population (Figures 1C, 1D, and S1D). Furthermore, retroviral
miR-17-92 expression blocked the induction of cellular senes-
cence in a sustained manner as measured by senescence-asso-
ciated b-galactosidase (SA-b-gal) staining (Figures 1E and S1E),
histone H4 lysine 20 trimethylation (H4K20me3) staining (Figures1E and S1F), and quantification of trimethylated histone H3
lysine 9 (H3K9me3) (Figure S1G). Similarly, in MYC-induced
hepatocellular carcinoma and osteosarcoma (Jain et al., 2002;
Shachaf et al., 2004), retroviral expression of miR-17-92 abro-
gated the induction of cellular senescence upon MYC suppres-
sion as shown by SA-b-gal staining (control versus miR-17-92:
19-fold versus 3-fold induction in hepatocellular carcinoma and
10-fold versus 3-fold induction in osteosarcoma; Figures S1H
and S1I). In contrast, miR-17-92 expression in three BCR-ABL-
driven B cell leukemia cell lines failed to rescue proliferative
arrest or apoptosis upon BCR-ABL inactivation (Figure S1J).
Hence, miR-17-92 specifically rescues the proliferative arrest,
apoptosis, and senescence upon MYC inactivation.
Next, we examined in vivo whether miR-17-92 expression
rescues the phenotypes of MYC inactivation. MYC-induced lym-
phoma cells expressing either an empty control vector or MSCV-
miR-17-92 were subcutaneously transplanted into syngeneic
FVB/N hosts. Tumor cells were allowed to grow in vivo for about
2 weeks before MYC inactivation by doxycycline administration
in the drinking water. Tumors were collected before and after
MYC inactivation for examination of apoptosis, proliferation,
and senescence (Figures 2A–2D). Phospho-histone H3 and
Ki67 staining was used tomeasure mitotic and proliferative cells,
respectively. Cleaved-caspase-3 stainingwasused for apoptotic
cells and SA-b-gal and H4K20me3 staining was used for senes-
cent cells. Upon MYC inactivation, in the control lymphoma
versus lymphomas with miR-17-92 expression, there was a
67% versus 15% decrease in phospho-histone H3 staining and
an 85% versus 25% decrease in Ki67 staining (Figures 2A and
S2), a 60% increase versus no change in cleaved-caspase-3
staining (Figure 2B), and a 3-fold increase versus no change in
SA-b-gal and H4K20me3 staining (Figures 2C and 2D). Thus,
miR-17-92expressionpreventedMYC inactivation from inducing
proliferative arrest, apoptosis, and senescence in vivo.
MYC viamiR-17-92 Regulates Specific Target Genes
We reasoned that MYC, throughmiR-17-92, regulates a specific
subset of genes responsible for maintaining autonomous prolif-
eration and survival. Since the expression ofMYC ormiR-17-92
can be turned off independently in our conditional system,
this allows for the screening of genes regulated by MYC or
miR-17-92 (Figures 1B andS3). The genes that were differentially
expressed before and after MYC inactivation in the control
lymphoma were categorized as MYC regulated. The genes that
were differentially expressed between the control lymphoma
and retroviral miR-17-92-expressing lymphoma when MYC
was turned off in both populations were defined as miR-17-92-
regulated (Figure S3). The specific subset of MYC target genes
regulated through miR-17-92 would appear to be coregulated
by both MYC andmiR-17-92 (Figures S3 and 3A). By comparing
the microarray gene expression profiles of the control lym-
phoma versus miR-17-92-expressing lymphoma upon MYC
inactivation, we found that 70% of miR-17-92-regulated genes
were also regulated by MYC (Figure 3A). The 401 overlapping
genes coregulated by MYC and miR-17-92 were further
separated into the upregulated and downreglated groups
(Figure 3B). Among the genes upregulated by both MYC and
miR-17-92, there was an enrichment of genes involved in DNA
replication, repair, and cell cycle (Figure 3C). Notably, the genesCancer Cell 26, 262–272, August 11, 2014 ª2014 Elsevier Inc. 263
Figure 1. miR-17-92 Expression In Vitro Rescues MYC Oncogene Addiction by Sustaining Proliferation and Blocking Apoptosis and
Senescence
(A) Diagram of cellular changes upon MYC inactivation in MYC-driven tumors.
(B) Experimental strategy to sustainmiR-17-92with retroviral expression. The endogenousmiR-17-92 is shown in gray, while the exogenousMSCV-miR-17-92 is
shown in blue.
(C) Cell cycle analysis of tumor cells over a 5-day time course with flow cytometry after propidium iodide staining. The numbers indicate the percentage of cells in
different phases of the cell cycle. The experiments were repeated three times with similar results.
(D) Annexin V/7-AAD staining showing apoptotic cells over a 5-day time course of MYC inactivation. The numbers in the upper right quadrant indicate the
percentage of apoptotic cells. The experiments were repeated three times with similar results.
(E) H4K20me3 and SA-b-gal staining of tumor cells after MYC inactivation for 5 days. The control cells are kept alive with Bim shRNA knockdown and Bcl-xL
overexpression. The numbers in the upper right quadrant indicate the percentage of cells stained positive. Cell nuclei in the H4K20me3 panel were stained with
DAPI. The experiments were repeated twice with similar results.
Scale bars, 50 mm. See also Figure S1.
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Figure 2. miR-17-92 Expression In Vivo Mediates MYC Oncogene Addiction by Sustaining Proliferation and Blocking Apoptosis and
Senescence
(A) Phospho-histone H3 staining showing cells in the metaphase of the cell cycle 4 days after MYC inactivation. The y axis denotes the number of positive staining
cells per 203 magnification field.
(B) Cleaved-caspase 3 showing apoptotic cells 4 days after MYC inactivation. The y axis denotes the number of positive staining cells per 203magnification field.
(C) SA-b-gal staining four days after MYC inactivation. The y axis denotes the percentage of area with positive SA-b-gal staining.
(D) H4K20me3 staining 4 days after MYC inactivation. The y axis denotes the percentage of cells with positive staining.
Results are presented as mean ± SEM, and n = 4 (A–D). Student’s t test: *p < 0.05; **p < 0.01. Scale bars, 50 mm. See also Figure S2.
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MYC through miR-17-92 Maintains a Neoplastic Statedownregulated by both MYC and miR-17-92 had 4.6-fold more
miR-17-92 binding sites in their 30 UTR compared with upregu-
lated genes (32% in downregulated versus 7% in upregulated
genes; Tables S1 and S2). We inferred that these downregulated
genes are directly regulated by miR-17-92 binding.
Our gene list was further refined by only including genes
with at least twomiR-17-92 binding sites in their 30 UTR, as pre-
dicted by each of three microRNA target scanning programs
(miRanda, Targetscan, and miRWalk) (Figures 3B and 3D; Table
S3). Among these 15 genes were four chromatin modifiers that
have not been previously reported as MYC ormiR-17-92 targets
(Sin3b, Hbp1, Suv420h1, and Btg1). Also identified was the
apoptosis regulator, Bim, which has been reported previously
to be a miR-17-92 target (Ventura et al., 2008; Xiao et al.,
2008) (Figure 3D). Notably, all of these genes have been associ-
ated with proliferative control, senescence, and/or apoptosis
(Berthet et al., 2002; David et al., 2008; Roninson, 2003; Swan-
son et al., 2004; van Oevelen et al., 2010). Thus, we focused
our subsequent efforts on assessing whether these MYC-miR-
17-92 target genes could contribute to the consequences of
MYC suppression in tumors.
We examined if these miR-17-92 targets were directly regu-
lated by MYC and miR-17-92. First, MYC inactivation induced
the protein expression of Sin3b, Hbp1, Suv420h1, Btg1, and all
three Bim isoforms in control, but not miR-17-92-expressing
cells as measured by western blot analysis (Figures 4A andS4). Second, to validate whether these genes are direct targets
ofmiR-17-92, a dual luciferase assay was performed by cloning
30 UTR fragments of all five genes, with either wild-type ormutant
miR-17-92 sites, downstream of the firefly luciferase coding re-
gion (Figure 4B, upper panel). Compared with mutant 30 UTRs
lackingmiR-17-92 binding sites, the wild-type 30 UTRs conferred
significant repression as shown by the 20%–60% lower firefly/
renilla ratio (Figure 4B, lower panel). Hence, Sin3b, Hbp1,
Suv420h1, Btg1, and Bim are regulated by MYC in a miR-17-
92-dependent manner.
Next, we examined if MYC viamiR-17-92was regulating chro-
matin through each of these gene products. Sin3b and Hbp1
have been shown to be candidate target genes of miR-19 (Mu
et al., 2009). Sin3b interacts with Hbp1 and recruits histone de-
acetylases (HDACs) to repress the transcription of genes related
to proliferation, such as Aurkb, Mybl2, Cdc6, and Bub1b (David
et al., 2008; Swanson et al., 2004; van Oevelen et al., 2010).
Indeed, these genes were upregulated by miR-17-92 and MYC
(Figure 3C; Table S1). Upon MYC inactivation, there was a 3-
to 8-fold increase versus a 2-fold increase in Sin3b binding to
these promoters in the control lymphoma versusmiR-17-92-ex-
pressing lymphoma according to a chromatin immunoprecipita-
tion assay (Figure 4C). Thus, the induction of Sin3b and Hbp1
upon MYC inactivation may contribute to proliferative arrest
and cellular senescence by silencing genes related to prolifera-
tion and cell cycle.Cancer Cell 26, 262–272, August 11, 2014 ª2014 Elsevier Inc. 265
A B
C
D
Figure 3. Identification of miR-17-92 Target
Genes by Comparative Analysis of Genes
Regulated by MYC and miR-17-92
(A) Venn diagram of genes regulated by both MYC
and miR-17-92.
(B) Flowchart showing the analysis of the genes
coregulated by MYC and miR-17-92. Genes were
separated into either upregulated or down-
regulated groups and analyzed for functional
annotation and enrichment of miR-17-92 binding
sites.
(C) Functional categories of genes upregulated by
both MYC and miR-17-92 according to DAVID
bioinformatic resources. The percentage refers to
the number of genes within a particular category in
relation to the total number of genes that have a
Gene Ontology annotation.
(D) Candidate target genes with multiple miR-17-
92 binding sites. The histone modifiers and Bim
were indicated with asterisks.
See also Figure S3 and Tables S1, S2, and S3.
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MYC through miR-17-92 Maintains a Neoplastic StateNotably, Suv420h1 is a histone methyltransferase that cata-
lyzes dimethylation and trimethylation of histone H4 lysine 20
(H4K20me2 and H4K20me3) (Fraga et al., 2005; Greer and Shi,
2012). H4K20me3 is a marker of heterochromatin formation
and senescence, and its loss is a common hallmark of human
cancer (Fraga et al., 2005; Greer and Shi, 2012; Nelson, 2012).
Upon MYC inactivation, there was an induction of both
H4K20me2 and H4K20me3 in control lymphoma cells, but not
miR-17-92-expressing lymphoma cells (Figure 4D). In contrast,
the monomethylated H4K20me1, catalyzed by Setd8 (Greer
and Shi, 2012), did not increase in either control or miR-17-92-
expressing lymphoma cells (Figure 4D), indicating that the induc-
tion of Suv420h1 specifically increases the dimethylation and
trimethylation of H4K20. Finally, Btg1 is a tumor suppressor
that can activate histonemethyltransferase Prmt1 to dimethylate
histone H4 arginine 3 (H4R3me2) (Berthet et al., 2002; Lin et al.,
1996). Upon MYC inactivation, there was an accumulation of
H4R3me2 in control cells, but not miR-17-92-expressing cells
(Figure 4D). Therefore, MYC inactivation viamiR-17-92 regulates
the biological function of the chromatin regulatory genes Sin3b,
Hbp1, Suv420h1, and Btg1.
Suppression of Sin3b, Hbp1, Suv420h1, Btg1, and Bim
Significantly RecapitulatesmiR-17-92 Function
Our results suggest that suppression of the four epigenetic reg-
ulators (Sin3b, Hbp1, Suv420h1, and Btg1, hereafter referred to
as SHSB) and the proapoptotic protein Bim may contribute to
MYC’s ability to maintain tumorigenesis. To examine this, the
miR-30-based retroviral short hairpin RNAs (shRNAs) were
used to knock down the target genes individually or collectively
in MYC-induced lymphoma cells. The target mRNA was
knocked down to levels between 6% and 20% of the scrambled
control (Figure S5A). Knocking down the expression of
Suv420h1 and Btg1 reduced the levels of H4K20me2/3 and
H4R3me2, respectively (Figures 4E and 4F). After 24 hr of MYC
inactivation, lymphoma cells with individual knockdown of the
chromatin modifiers exhibited a modest block in proliferative ar-
rest, with 19%–30% of cells still remaining in S/G2/M phases266 Cancer Cell 26, 262–272, August 11, 2014 ª2014 Elsevier Inc.compared to only 11% for control cells (Sin3b: 25%; Hbp1:
25%; Suv420h1: 35%; Btg1: 19%; Figure S5B). Concurrently
knocking down all five miR-17-92 target genes (Bim and
SHSB), modestly delayed the proliferative arrest after MYC inac-
tivation as shown by flow cytometric analysis of the cell cycle
distribution (Figures 5A and 5B). The knockdown of Bim alone
reduced the induction of apoptosis following MYC inactivation,
whereas the combined knockdown of Bim and SHSB further
decreased the rate of apoptosis (Figures 5C and S5C). Hence,
these data suggest thatmiR-17-92 regulation of its target genes
Sin3b, Hbp1, Suv420h1, Btg1, and Bim is required for prolifera-
tive arrest and apoptosis upon MYC inactivation.
Cellular senescence is characterized by a state of permanent
cell cycle arrest (Guney and Sedivy, 2006; Nardella et al., 2011).
We have shown previously that even brief suppression of MYC
can induce senescence and result in sustained tumor regression
(Jain et al., 2002). We tested if cell cycle arrest induced by MYC
inactivation is reversible (Figure 5D, ON, OFF, and BACK ON).
Upon MYC inactivation, control lymphoma cells progress from
cell cycle arrest to high levels of apoptosis, with few viable cells
remaining by 4–5 days after oncogene withdrawal (Figures 1C
and 1D). To specifically examine the effect of MYC inactivation
on cell cycle arrest, independently from apoptosis, we utilized
lymphoma cells with the shRNA-mediated knockdown of Bim.
Upon MYC inactivation, lymphoma cells with Bim knockdown
persisted and underwent proliferative arrest. Moreover, they
remained arrested even after reactivation of MYC (Figure 5D,
upper panel). This irreversible cell cycle arrest indicated the in-
duction of senescence by MYC inactivation. In contrast, lym-
phoma cells expressing miR-17-92 or with the knockdown of
Bim and SHSB resumed proliferation upon MYC reactivation
(Figure 5D, middle and lower panels). Therefore, the expression
of miR-17-92 or the suppression of the miR-17-92 target genes
Sin3b, Hbp1, Sub420h1, and Btg1 prevents the induction of
senescence upon MYC inactivation.
The shRNA-mediated suppression of Bim and SHSB also
impeded the in vivo proliferative arrest, apoptosis, and senes-
cence upon MYC inactivation. Tumor cells were transplanted
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Figure 4. Validation of Target Genes of miR-
17-92
(A) Changes in the expression of Bim and histone
modifiers as detected by western blot 3 days after
MYC inactivation.
(B) Top: wild-type (WT) and mutant (Mut) 30 UTR
reporter constructs. Bottom: dual luciferase assay
using 30 UTR reporters. The firefly luciferase signals
were normalized with the internal control renilla
luciferase. Results are presented as mean ± SEM.
Student’s t test: *p < 0.05; **p < 0.01.
(C) Chromatin immunoprecipitation with Sin3b
antibody showing binding of Sin3b to promoters of
four proliferation-related genes upon MYC inacti-
vation. MYC OFF samples were taken at 2 days
after MYC inactivation. PCR with Hoxa9 promoter
specific primers was included as a negative control.
Data shown are averages of two experiments and
are presented as mean ± SEM.
(D) Changes in histone H4 lysine 20 and arginine 3
methylation status upon MYC inactivation. The
mono-, di-, and trimethylation of H4K20 and dime-
thylation of H4R3 are shown. The MYC OFF time
course includes days 0, 1, 2, and 3. The respective
enzymes catalyzing each of the modifications are
shown on the left side of the lanes.
(E) Western blot analysis of di- and trimethylation of
H4K20 in the presence of Suv420h1 knockdown
(KD).
(F) Western blot analysis of dimethylation of H4R3 in
the presence of Btg1 knockdown.
See also Figure S4.
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MYC through miR-17-92 Maintains a Neoplastic Statesubcutaneously into syngeneic FVB/N hosts and grown for
about 2 weeks before MYC inactivation by doxycycline adminis-
tration in the drinking water. In control lymphoma versus
lymphomas with Bim and SHSB knockdown, there was a 4-
fold decrease versus 1-fold decrease in phospho-histone H3
staining, a 1.5-fold increase versus no change in cleaved-cas-
pase-3 staining, and a 3-fold versus less than 1-fold increase
in SA-b-gal staining (Figures 6A–6C), similar to what was
observed for miR-17-92 expression (Figures 2 and 6D). Thus,
miR-17-92 target genes Sin3b, Hbp1, Suv420h1, Btg1, and
Bim are required for the induction of proliferative arrest,
apoptosis, and senescence in vivo upon MYC inactivation.
Suppression of Sin3b, Hbp1, Suv420h1, Btg1, and Bim
Abrogates Sustained Tumor Regression upon
MYC Inactivation
Since miR-17-92 expression and knockdown of miR-17-92
target genes significantly block the induction of proliferative
arrest, apoptosis, and senescence both in vitro and in vivo, we
examined their impact on sustained tumor regression upon
MYC inactivation. MYC inactivation in lymphoma induced rapid
tumor regression within 6 days (Figure 6E), without evidence of
lymphoma recurrence even after 6 months of continuous obser-
vation (Figure 6F). In contrast, the lymphomas with enforced
retroviral miR-17-92 expression regressed only after 14 days
and 80% of tumors reoccurred within 6 weeks (Figures 6E and
6F). Compared with the dramatic delay in tumor regression
with miR-17-92 expression, the knockdown of either Bim orBim combined with SHSB modestly delayed the kinetics of
tumor regression (Figure 6E). Interestingly, although Bim knock-
down was not associated with any tumor recurrence, the com-
bined knockdown of Bim and SHSB was associated with the
recurrence of 50% of tumors (Figure 6F). After prolonged MYC
inactivation, the recurrent tumors eventually regained high levels
of MYC expression, similar to what we have described previ-
ously (Figure S6) (Choi et al., 2011). Hence, the expression of
miR-17-92 or the suppression of miR-17-92 target genes
Sin3b, Hbp1, Suv420h1, Btg1, and Bim prevented sustained
tumor regression upon MYC inactivation.
DISCUSSION
Wehave found thatMYC throughmiR-17-92 directly suppresses
the expression of chromatin regulatory genes Sin3b, Hbp1,
Suv420h1, and Btg1 and proapoptotic gene Bim. The suppres-
sion of these defined factors is causally required to maintain sur-
vival, autonomous proliferation, and self-renewal. Our results
have general implications for how MYC maintains a neoplastic
state.
MYC is known to globally regulate gene and protein expres-
sion (Dang, 2012). Many studies have identified hundreds of
genes associated with MYC overexpression and tumorigenesis
(Kim et al., 2008; Schlosser et al., 2005; Zeller et al., 2006). The
expectation is that a similarmultitude of geneswould be required
by MYC to initiate and maintain a neoplastic state. Surprisingly,
we found that a single microRNA cluster, miR-17-92, amongCancer Cell 26, 262–272, August 11, 2014 ª2014 Elsevier Inc. 267
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Figure 5. Suppression of Bim and the
Chromatin Modifiers Delays Proliferative
Arrest and Blocks Apoptosis and Senes-
cence upon MYC Inactivation In Vitro
(A) Cell cycle distribution of cells with combined
knockdowns of SHSB and Bim upon MYC inacti-
vation for 5 days. The numbers indicate the per-
centage of cells in different phases of the cell cycle.
(B) Bar graph summarizing data shown in Figure 5A.
Different phases of the cell cycle were color coded.
(C) Apoptosis of tumor cells with knockdown of
Bim and SHSB upon MYC inactivation for 4 days.
The numbers in the upper right quadrant indicate
the percentage of apoptotic cells. A detailed 5-day
time course is shown in Figure S5.
(D) Cell cycle distribution of tumor cells upon MYC
inactivation and reactivation. MYC OFF samples
were taken at 4 days of MYC inactivation with
doxycycline treatment. MYC BACK ON samples
were taken at 3 days after MYC reactivation by
removing doxycycline. The events shown are
gated on live cells. The numbers indicate the
percentage of cells in either the G1/G0 or the S/
G2/M phase of the cell cycle.
The experiments were repeated three times with
similar results. See also Figure S5.
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MYC through miR-17-92 Maintains a Neoplastic Statethousands of genes controlled byMYCcanmaintain a neoplastic
state in MYC-induced tumors by sustaining autonomous prolif-
eration and survival. We found that this mechanism was specific
to MYC and unique to miR-17-92. Furthermore, the function
of miR-17-92 can be partially attributed to the suppression of
a small number of target genes, such as the chromatin regula-
tory genes Sin3b, Hbp1, Suv420h1, and Btg1, as well as the
proapoptotic gene Bim. Our results highlight how MYC main-
tains tumorigenesis through the regulation ofmiR-17-92-depen-
dent epigenetic and survival programs.
Oncogene-induced tumorigenesis is generally suppressed
through intrinsic barriers, such as apoptosis and senescence
(Braig et al., 2005; Lowe et al., 2004; Nardella et al., 2011). The
inactivation of a driver oncogene can restore these tumor sup-
pressor mechanisms, even in a tumor that is genetically complex
(Karlsson et al., 2003), thereby eliciting the phenomenon of
oncogene addiction (Felsher, 2008; Weinstein, 2002). Hence,
our results suggest that MYC via miR-17-92 maintains autono-
mous proliferation, self-renewal, and survival. Correspondingly,
MYC inactivation induces a loss of distinguishing features of
tumors as a consequence of restoration of proliferative arrest,
apoptosis, and senescence (Figure 7).
We have identified specific miR-17-92 target genes that
are essential for the reversal of neoplasia upon MYC inactiva-
tion. These genes drive proliferation arrest, senescence, and
apoptosis by regulating chromatin modification and apoptosis.
Sin3b interacts with Hbp1 and recruits HDACs to silence prolif-
eration-related genes and mediate cell cycle exit and senes-
cence (David et al., 2008; Grandinetti et al., 2009; Swanson
et al., 2004). Suv420h1 is a histone methyltransferase that dime-
thylates and trimethylates H4K20 (Fraga et al., 2005; Greer and
Shi, 2012). H4K20me3 is known to direct chromatin compaction
and is a marker of heterochromatin formation and senescence
(Greer and Shi, 2012; Lu et al., 2008; Nelson, 2012). Loss of
H4K20me3 is a common feature in human cancer (Fraga268 Cancer Cell 26, 262–272, August 11, 2014 ª2014 Elsevier Inc.et al., 2005). Btg1 is a tumor suppressor that is frequently lost
in acute lymphoblastic leukemia (Lundin et al., 2012; Waanders
et al., 2012). It is also a biomarker of chemotherapy-induced
cellular senescence (Roninson, 2003). Finally, Bim is a major
tumor suppressor in MYC-induced lymphomagenesis (Egle
et al., 2004). Bim is also frequently lost in human B cell lym-
phomas, and its loss can cause chemoresistance in patients
(Richter-Larrea et al., 2010). Thus, these miR-17-92 targets
are some of the critical players in the maintenance of the
neoplastic state by MYC.
Recently, it has been shown that MYC can function as a tran-
scriptional amplifier of the already expressed genes within the
cells without specificity (Lin et al., 2012; Nie et al., 2012). It is a
remarkable finding and explains one aspect of MYC function
that is consistent with prior studies (Dang, 2012; Guccione
et al., 2006; Guney and Sedivy, 2006; Varlakhanova and Knoep-
fler, 2009). However, whether the transcriptional amplifier mech-
anism is required for MYC to maintain the neoplastic state is not
known. Moreover, MYC’s function as an amplifier is likely only
one of its many functions and does not account for the ability
of MYC to suppress gene expression, nor does it provide an
explanation for gene-specific effects on expression (Walz
et al., 2013). Our results highlight an additional mechanism by
which MYC controls several essential features of a neoplastic
state (Figure 7). MYC, through miR-17-92, controls a general
ON and OFF switch of chromatin state and thereby regulates
the decision between survival versus death and self-renewal
versus senescence. Our findings are also complementary to
MYC’s role in transcriptional amplification. High levels of MYC
can keep the chromatin transcriptionally accessible and allow
for transcriptional amplification. When MYC is turned off, many
genes are downregulated by the amplifier mechanism and this
likely reduces the ability of tumor cells to grow and proliferate.
However, the suppression of miR-17-92 upon MYC inactiva-
tion allows the induction of many genes, including chromatin
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Figure 6. Suppression of Bim and the Chromatin Modifiers Delays Proliferative Arrest, Blocks Apoptosis and Senescence, and Abrogates
Sustained Tumor Regression upon MYC Inactivation In Vivo
(A) Phospho-histone H3 staining showing cells in the metaphase of the cell cycle 4 days after MYC inactivation. The y axis denotes the number of positive staining
cells per 403 magnification field.
(B) Cleaved-caspase 3 showing apoptotic cells 4 days after MYC inactivation. The y axis denotes the number of positive staining cells per 403magnification field.
(C) SA-b-gal staining at 4 days after MYC inactivation. The y axis denotes the percentage of area with positive SA-b-gal staining, and n = 3. For panels (A)–(C), the
results are presented as mean ± SEM. Student’s t test: *p < 0.05; **p < 0.01. Scale bars, 50 mm.
(D) Comparison of in vivo induction of proliferative arrest, apoptosis, and senescence upon MYC inactivation in control lymphomas, lymphomas with retroviral
miR-17-92, and lymphomas with knockdown of Bim and SHSB. To calculate the fold induction of proliferative arrest, we used the MYC ON/MYC OFF ratio for
phospho-histone H3 staining. To calculate the fold induction of apoptosis and senescence, we used the MYC OFF/MYC ON ratio of cleaved-caspase-3 and
SA-b-gal staining, respectively. The fold induction was computed by combining data presented in Figures 2 and 6A–6C. The dashed line indicates no
induction.
(E) In vivo regression of transplanted tumors in severe combined immunodeficiency mouse host; n = 4–6. FormiR-17-92 versus control, **p < 0.05 for days 3–14.
For Bim KD or Bim&SHSB KD versus control, *p < 0.05 for days 5–8. The comparisons were made with the two-tailed Student’s t test.
(F) In vivo tumor reoccurrence upon MYC inactivation in syngeneic wild-type FVB/N mice. Tumor bearing mice were monitored for 6 weeks of doxycycline
administration in drinking water. The mice were euthanized when the diameters of the relapsed tumors reach 1 cm; n = 10–16.
Log rank test: p < 0.001 for tumors with Bim&SHSB KD, and p < 0.0001 for tumors with miR-17-92 expression. See also Figure S6.
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MYC through miR-17-92 Maintains a Neoplastic Statemodifiers and apoptosis regulators involved in apoptosis and
senescence (Figure 7). Hence, MYC inactivation leads to a
change in the neoplastic state.
MYC has been shown before to modulate global euchromatin
structure that may contribute to self-renewal and pluripotency,
but the specific mechanism has been elusive (Knoepfler et al.,
2006; Varlakhanova and Knoepfler, 2009). Our finding thatMYC, throughmiR-17-92, regulates the heterochromatin forma-
tion may provide an explanation. Hence, MYC suppression in
cancer cells results in irreversible changes in gene expression
and the permanent loss of a neoplastic phenotype (Jain et al.,
2002). We infer that MYC’s ability to sustain autonomous prolif-
eration, self-renewal, and survival is mediated through amiR-17-
92-dependent chromatin regulatory and survival switch. TheCancer Cell 26, 262–272, August 11, 2014 ª2014 Elsevier Inc. 269
Figure 7. Model Illustrating that MYC,
through miR-17-92 and Its Target Genes,
Controls a Chromatin Regulatory and Sur-
vival Switch that Is Required to Sustain a
Neoplastic State
MYC through miR-17-92 suppresses specific
genes to maintain autonomous proliferation, self-
renewal, and survival. Correspondingly, MYC
inactivation induces a loss of neoplastic features
as a consequence of restoration of proliferative
arrest, apoptosis, and senescence.
Cancer Cell
MYC through miR-17-92 Maintains a Neoplastic Stateshutoff of this epigenetic switch contributes to the mechanism of
MYC-associated oncogene addiction.
EXPERIMENTAL PROCEDURES
Cell Lines, DNA Constructs, and Viruses
Conditional lymphoma and leukemia cell lines were derived from Em-tTA/tet-
O-MYC mice. MYC inactivation was achieved with doxycycline treatment.
The miR-17-92 was cloned into pMSCV retroviral vectors. Virus production
and infection of tumor cells was performed as previously reported (Wu et al.,
2007). Construction of the 30 UTR luciferase reporters and the shRNAs can
be found in the Supplemental Experimental Procedures.
Tumor Transplantation
All animal experiments were approved by Stanford University’s Administrative
Panel on Laboratory Animal Care (APLAC) and in accordance with national
guidelines. The conditional MYC lymphoma cell line was transplanted into
host mice and allowed to grow to 1.5 cm in diameter before MYC inactivation
with doxycycline. Tumor diameters were measured with a caliper. Tumor vol-
ume (V) was calculated as: V = ab2/2, where a indicates length (millimeters) and
b indicates breadth (millimeters). Further details can be found in the Supple-
mental Experimental Procedures.
Flow Cytometry, MicroRNA Quantification, Western Blot,
Immunohistochemistry, SA-b-gal Staining, and
Chromatin Immunoprecipitation
The microRNAs were quantified with TaqMan microRNA assay kits (Applied
Biosystems). Western blotting, immunofluorescence, SA-b-gal staining, and
chromatin immunoprecipitation were performed as described (van Oevelen
et al., 2010; Wu et al., 2007). Details can be found in the Supplemental Exper-
imental Procedures.
Microarray Analysis
Control and miR-17-92-expressing cell lines were used for the microarray
analysis. MYCONandMYCOFF samples were collected at 0 hr and 48 hr after
MYC inactivation. Details of the microarray analysis can be found in the
Supplemental Experimental Procedures.
Multiple Knockdown with shRNAs
The individual knockdown of miR-17-92 target genes was accomplished
using MSCV-LTRmiR30-PIG (LMP) shRNAs (OpenBiosystems). For multiple
knockdown, the shRNAs were cloned into vectors with different drug selection
markers to allow for simultaneous knockdown of multiple genes in the
same cell. Further details can be found in the Supplemental Experimental
Procedures.
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